这种成分是什么?

이 원료는 로진을 수소첨가하여 얻은 것이다.

成分列表

成分词典

HYDROGENATED ROSIN

产品中实际含有多少

暂无产品标示该成分含量。

含该成分的产品中，4 款将其列在 1% 线之前，0 款列在之后（通常不超过 1%）。

含有此成分的产品

已确认 4 款中的 4 款 · 按含量充足程度排序

定义

Rosin, hydrogenated

化妆品中的作用

在涂抹处形成薄膜FILM FORMING为产品增添香味PERFUMING调节黏度VISCOSITY CONTROLLING

安全与法规参考

未列入韩国有毒物质 GHS 分类 · 现有化学物质

来源: 韩国有毒物质 GHS 信息（环境公团）

详细资料——标示名称、识别编号、物性、试验记录、文献

官方标示名称和定义

日本化妆品工业联合会标示名称水添ロジン: 本品は、ロジン（＊）を水素添加したものである。

来源: 日本化妆品工业联合会标示名称

别名和识别信息

HYDROGENATED ROSININCI하이드로제네이티드로진韩国标示名称（食药处标准名）Rosin, hydrogenated同义名水添ロジン日本标示名称

CAS No.化学物质登记号: 65997-06-0
EC No.欧盟化学品目录编号: 266-041-3
DTXSID美国EPA化学品编号: DTXSID0028294

实测物性

性状: 固体
熔点/凝固点: 75 ℃
闪点: 203 ℃
比重: 1.05

这是对物质本身测得的数值。韩国安全保健公团（KOSHA）的资料仅供编写和审核安全数据表参考，并非原料商品的规格。

来源: 韩国安全保健公团安全数据表

产品实际使用的用途

这是向美国 EPA 申报含该成分的 45 款产品的用途。其中包括化妆品以外的产品，排在前几行的即为该成分的主要用途。

Adhesion/cohesion promoter20
Fragrance11
Plasticizer4
Lubricating agent2
Pigment2
Processing aids not otherwise specified1
Monomers1
Film former1

其余用途 3 项

Viscosity modifier1
Binder1
Surface modifier1

来源: 美国EPA CompTox

刺激与致敏试验记录

记录有皮肤试验 14 项、眼部试验 3 项。

归类为刺激性高1 项归类为低22 项

各项试验结论不一（最多的结论占 4%），因此不能断定该成分有刺激性。这是对原料本身的试验记录，与成品中所含浓度下的刺激性不同。

查看全部 17 项试验

Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · OECD Guideline 404 (Acute Dermal Irritation / Corrosion) equivalent or similar to
Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · other guideline: standard Draize method equivalent or similar to
Not likely to be sensitizing
skin sensitisation: in vivo (non-LLNA) · Screening · equivalent or similar to OECD Guideline 406 (Skin Sensitisation)
Not likely to be sensitizing
skin sensitisation: in vivo (LLNA) · Screening · equivalent or similar to OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
High Frequency of Sensitization
skin sensitisation: in vivo (LLNA) · Screening · according to OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay) according to EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · OECD Guideline 404 (Acute Dermal Irritation / Corrosion) according to EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) according to
Not likely to be sensitizing
skin sensitisation: in vivo (non-LLNA) · Screening · according to OECD Guideline 406 (Skin Sensitisation)
Not likely to be sensitizing
skin sensitisation: in vivo (LLNA) · Screening · according to OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay) according to EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
Skin sensitisation - category 1
Skin Sensitization · Screening
Ambiguous
skin sensitisation: in vivo (LLNA) · Screening · according to OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
Category 6.5B (Category 1)
Skin Sensitization · Read Across
Category 6.3B (Category 3)
Skin Irritation · Read Across
Not likely to be sensitizing
skin sensitisation: in vivo (non-LLNA) · Screening · according to EU Method B.6 (Skin Sensitisation)
Not likely to be sensitizing
skin sensitisation: in vivo (non-LLNA) · Screening · according to OECD Guideline 406 (Skin Sensitisation) according to EU Method B.6 (Skin Sensitisation)
Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · OECD Guideline 405 (Acute Eye Irritation / Corrosion) equivalent or similar to
Severe Irritation
eye irritation: in vivo · Screening · OECD Guideline 405 (Acute Eye Irritation / Corrosion) according to
Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · OECD Guideline 405 (Acute Eye Irritation / Corrosion) according to EU Method B.5 (Acute Toxicity: Eye Irritation / Corrosion) according to